The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.

Trial Profile

The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin; Doxorubicin; Gemcitabine; Methotrexate; Paclitaxel; Vinblastine
  • Indications Bladder cancer; Ureteral-neoplasms; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms DUTRENEO
  • Most Recent Events

    • 23 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top